Summary
Intuitive Surgical, Inc. (ISRG) reported its first-quarter 2023 financial results, showcasing robust growth driven by increased da Vinci procedure volumes and strong performance in instruments and accessories. Total revenue grew 14% year-over-year to $1.7 billion, with instruments and accessories revenue up 22% to $986 million, largely fueled by a 26% increase in da Vinci procedures globally. While systems revenue remained flat year-over-year at $427 million, this was driven by higher leasing revenue, offsetting a greater proportion of systems placed under operating leases. The company maintained a strong installed base, with da Vinci systems growing 12% to 7,779 and Ion systems growing 131% to 376. Despite revenue growth, operating income saw a slight decrease of 5% to $388 million, primarily due to increased operating expenses, including higher R&D and SG&A costs related to investments in future growth and share-based compensation. The company's gross profit margin also compressed slightly to 65.6% from 67.9% in the prior year, impacted by higher component and labor costs. Intuitive Surgical ended the quarter with a healthy cash position of $6.58 billion, but significant share repurchases and capital expenditures are noted. Key risks and considerations include ongoing macroeconomic challenges such as inflation and rising interest rates, which may impact hospital capital spending, as well as supply chain constraints that continue to pose a challenge. The company is actively managing these risks while investing in innovation and expanding its global reach.
Financial Highlights
45 data points| Revenue | $1.70B |
| Cost of Revenue | $583.20M |
| Gross Profit | $1.11B |
| R&D Expenses | $244.90M |
| SG&A Expenses | $480.50M |
| Operating Expenses | $725.40M |
| Operating Income | $387.60M |
| Net Income | $355.30M |
| EPS (Basic) | $1.01 |
| EPS (Diluted) | $1.00 |
| Shares Outstanding (Basic) | 350.20M |
| Shares Outstanding (Diluted) | 356.00M |
Key Highlights
- 1Total revenue increased 14% to $1.70 billion for Q1 2023 compared to $1.49 billion in Q1 2022, driven by higher procedure volumes and instrument/accessory sales.
- 2Da Vinci procedures increased by 26% year-over-year, reaching approximately 540,000 in Q1 2023, demonstrating strong adoption and utilization.
- 3Instruments and accessories revenue grew 22% to $986 million, reflecting the direct correlation with procedure volume and recurring revenue streams.
- 4Systems revenue remained flat at $427 million due to a higher proportion of systems placed under operating leases, despite a slight increase in total system placements.
- 5Operating income decreased 5% to $388 million due to increased operating expenses, particularly in R&D and SG&A, reflecting investments in future growth and share-based compensation.
- 6Gross profit margin declined to 65.6% from 67.9% in the prior year, primarily due to increased component costs, labor costs, and inventory reserves.
- 7The company ended the quarter with a strong liquidity position, with cash, cash equivalents, and investments totaling $6.58 billion.